A randomized, phase II study of the anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancer

Cancer Medicine

Volumn 3, Issue 4, 2014, Pages 988-997

  Lin, Edward H ^a   Lenz, Heinz Josef ^b   Saleh, Mansoor N ^c   Mackenzie, Mary J ^d   Knost, James A ^e   Pathiraja, Kumudu ^f   Langdon, Ronald B ^f   Yao, Siu Long ^f   Lu, Brian D ^f  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Georgia Cancer Specialists   (United States)

^d LONDON HEALTH SCIENCES CENTRE   (Canada)

^e Illinois Cancer Care   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Colorectal cancer; IGF 1R; Monoclonal antibody; Robatumumab

Indexed keywords

FLUORODEOXYGLUCOSE F 18; ROBATUMUMAB; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C RECEPTOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ARTICLE; ASTHENIA; BACKACHE; BODY WEIGHT DISORDER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; FATIGUE; FEMALE; GAIT DISORDER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IMMUNOGENICITY; LIMB PAIN; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NAUSEA; OPEN STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RASH; STOMATITIS; URINARY TRACT INFECTION; VOMITING; XEROSTOMIA; CHEMICALLY INDUCED; CLINICAL TRIAL; COLORECTAL NEOPLASMS; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTOR, IGF TYPE 1; TREATMENT OUTCOME;

EID: 84929144064     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.263     Document Type: Article

References (31)

1. Pollak, M. 2008. Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer 8:915-928.
2. Pollak, M. 2012. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat. Rev. Cancer 12:159-169.
3. Ludovini, V., G. Bellezza, L. Pistola, F. Bianconi, L. Di Carlo, and A. Sidoni . 2009. High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann. Oncol. 20:842-849.
4. Barnes, C. J., K. Ohshiro, S. K. Rayala, A. K. El-Naggar, and R. Kumar . 2007. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin. Cancer Res. 13:4291-4299.
5. Cunningham, M. P., S. Essapen, H. Thomas, M. Green, D. P. Lovell, and C. Topham . 2006. Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients. Int. J. Oncol. 28:329-335.
6. Morgillo, F., W. Y. Kim, E. S. Kim, F. Ciardiello, W. K. Hong, and H. Y. Lee . 2007. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin. Cancer Res. 13:2795-2803.
7. Peters, G., S. Gongoll, C. Langner, M. Mengel, P. Piso, and J. Klempnauer . 2003. IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Arch. 443:139-145.
8. Hakam, A., T. J. Yeatman, L. Lu, L. Mora, G. Marcet, and S. V. Nicosia . 1999. Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum. Pathol. 30:1128-1133.
9. Liou, J. M., C. T. Shun, J. T. Liang, H. M. Chiu, M. J. Chen, and C. C. Chen . 2010. Plasma insulin-like growth factor-binding protein-2 levels as diagnostic and prognostic biomarker of colorectal cancer. J. Clin. Endocrinol. Metab. 95:1717-1725.
10. Inno, A., M. Di Salvatore, T. Cenci, M. Martini, A. Orlandi, and A. Strippoli . 2011. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? Clin. Colorectal Cancer 10:325-332.
11. Lambert, S., J. Vivario, J. Boniver, and R. Gol-Winkler . 1990. Abnormal expression and structural modification of the insulin-like growth-factor-II gene in human colorectal tumors. Int. J. Cancer 46:405-410.
12. Kawamoto, K., H. Onodera, S. Kan, S. Kondo, and M. Imamura . 1999. Possible paracrine mechanism of insulin-like growth factor-2 in the development of liver metastases from colorectal carcinoma. Cancer 85:18-25.
13. Ma, J., M. N. Pollak, E. Giovannucci, J. M. Chan, Y. Tao, C. H. Hennekens, et al. 1999. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J. Natl. Cancer Inst. 91:620-625.
14. Wolpin, B. M., J. A. Meyerhardt, A. T. Chan, K. Ng, J. A. Chan, K. Wu, et al. 2009. Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J. Clin. Oncol. 27:176-185.
15. Karp, D. D., L. G. Paz-Ares, S. Novello, P. Haluska, L. Garland, F. Cardenal, et al. 2009. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751, 871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J. Clin. Oncol. 27:2516-2522.
16. Reidy, D. L., E. Vakiani, M. G. Fakih, M. W. Saif, J. R. Hecht, N. Goodman-Davis, et al. 2010. Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J. Clin. Oncol. 28:4240-4246.
17. Naing, A., P. LoRusso, S. Fu, D. S. Hong, P. Anderson, R. S. Benjamin, et al. 2012. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin. Cancer Res. 18:2625-2631.
18. Reidy-Lagunes, D. L., E. Vakiani, M. F. Segal, E. M. Hollywood, L. H. Tang, D. B. Solit, et al. 2012. A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors. Cancer 118:4705-4800.
19. Wang, Y., J. Hailey, D. Williams, Y. Wang, P. Lipari, M. Malkowski, et al. 2005. Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Mol. Cancer Ther. 4:1214-1221.
20. Wang, Y., P. Lipari, X. Wang, J. Hailey, L. Liang, R. Ramos, et al. 2010. A fully human insulin-like growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts. Mol. Cancer Ther. 9:410-418.
21. Findlay, M., H. Young, D. Cunningham, A. Iveson, B. Cronin, T. Hickish, et al. 1996. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J. Clin. Oncol. 14:700-708.
22. Flamen, P., S. Stroobants, E. Van Cutsem, P. Dupont, G. Bormans, N. De Vadder, et al. 1999. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer. J. Clin. Oncol. 17:894-901.
23. Cascini, G. L., A. Avallone, P. Delrio, C. Guida, F. Tatangelo, P. Marone, et al. 2006. 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. J. Nucl. Med. 47:1241-1248.
24. Eisenhauer, E. A., P. Therasse, J. Bogaerts, L. H. Schwartz, D. Sargent, R. Ford, et al. 2009. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45:228-247.
25. Williams, A. C., H. Smartt, A. M. H-Zadeh, M. Macfarlane, C. Paraskeva, and T. J. Collard . 2007. Insulin-like growth factor binding protein 3 (IGFBP-3) potentiates TRAIL-induced apoptosis of human colorectal carcinoma cells through inhibition of NF-kappaB. Cell Death Differ. 14:137-145.
26. Fuchs, C. S., R. M. Goldberg, D. J. Sargent, J. A. Meyerhardt, B. M. Wolpin, E. M. Green, et al. 2008. Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. Clin. Cancer Res. 14:8263-8269.
27. Jacobs, E. T., M. E. Martinez, D. S. Alberts, E. L. Ashbeck, S. M. Gapstur, P. Lance, et al. 2008. Plasma insulin-like growth factor I is inversely associated with colorectal adenoma recurrence: a novel hypothesis. Cancer Epidemiol. Biomarkers Prev. 17:300-305.
28. Watkins, D. J., J. Tabernero, H. Schmoll, T. Trarbach, F. J. Ramos, J. Howe, et al. 2011. A randomized phase II/III study of the anti-IGF-1R antibody MK-0646 (dalotuzumab) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory metastatic colorectal cancer (mCRC) with wild-type (wt) KRAS status. J. Clin. Oncol. 29(Suppl. 20):3501.
29. Becerra, C., R. Salazar, R. Garcia-Carbonero, A. L. Thomas, F. Vázquez-Mazón, J. Cassidy, et al. 2011. Phase II trial of figitumumab in patients with refractory, metastatic colorectal cancer (mCRC). J. Clin. Oncol. 29(Suppl. 20):3525.
30. Cancer Genome Atlas Network. 2012. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330-337.
31. Tolcher, A. W., J. Sarantopoulos, A. Patnaik, K. Papadopoulos, C. C. Lin, J. Rodon, et al. 2009. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J. Clin. Oncol. 27:5800-5807.